Menu
Recruiting NCT06201403

Mechanical Properties of Peripheral and Accessory Respiratory Muscles in Chronic Obstructive Pulmonary Disease Patients

— Observational COPD

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Determination of biomechanical properties of muscles.
Who it may be relevant to
Registry conditions: COPD. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Turkey (Türkiye)
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

The biomechanical properties of accessory respiratory muscles and peripheral muscles of COPD and healthy subjects will be measured and compared with the MyotonPro device.

Interventions

  • Diagnostic test Determination of biomechanical properties of muscles
    All evaluations will be performed with a MyotonPRO (Myoton AS., Tallinn, Estonia) digital palpation device. The data of the cases to be evaluated and the patterns related to the measurements will be transferred to the device by establishing a computer connection. Measurements will be performed unilaterally. The measurement point of the subjects' unilateral muscles will first be marked with a pencil. The physiotherapist will hold the device vertically and apply downward pressure (18N) to the musc

Primary outcome measures

  • M.Sternocleidomastoideus (SCM) myotonometric measurement [Time frame: 107 millisecond]
  • M. Trapezius myotonometric measurement [Time frame: 107 millisecond]
  • M. Biceps brachii myotonometric measurement [Time frame: 107 millisecond]
  • M. Pectoralis Major (PM) myotonometric measurement [Time frame: 107 millisecond]
  • M. Rectus abdominis (RA) myotonometric measurement [Time frame: 107 millisecond]
  • M.Rectus femoris myotonometric measurement [Time frame: 107 millisecond]
  • M.Vastus lateralis myotonometric measurement [Time frame: 107 millisecond]
  • M. Tibialis anterior myotonometric measurement [Time frame: 107 millisecond]

Eligibility criteria

Inclusion criteria

  • Being diagnosed with group C and D COPD according to GOLD staging
  • Having been using the same medications for the last 4 weeks
  • No additional comorbid diseases of the orthopedic, neurological or cardiac system

Exclusion criteria

  • Presence of another respiratory system disease other than COPD
  • Patients who have had an acute COPD exacerbation in the last 4 weeks
  • Patients experiencing COPD exacerbations during the study protocol
  • Presence of fatty tissue at the measurement points, which may impair the measurement quality.
  • Have already participated in another clinical trial within the last 30 days that may affect the results of the study.

Inclusion Criteria for Healthy Cases

  • Being over 18 years of age
  • Not having any diagnosed chronic disease
  • Not being a smoker

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Study design

Observational model
Case-control

Study locations

Turkey (Türkiye) · 1 center
  • Yedikule Chest Disease Hospital — Istanbul

Identifiers

NCT: NCT06201403 · COPD&Myoton

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗